56-Year-Old Woman Relapsing Following Induction Therapy and Autologous Stem Cell Transplantation
Jointly provided by
Support for this activity has been provided through educational grants from Amgen; Bristol-Myers Squibb; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Release date: 10/21/2016
Expiration date: 10/21/2017
Estimated time to complete: 0.75 hours
In 2015 four new agents were approved for the treatment of MM in the salvage setting, equipping oncology health professionals with more therapeutic options than ever before. For oncology nurses, however, this progress brings the challenge of managing new treatment-related toxicities. This interactive e-learning activity provides updates on current practices in MM patient care, using a patient case study that invites learners to participate in the decision-making processes that will maximize treatment outcomes for patients with relapsed/refractory MM.
Page Bertolotti, RN, BSN, OCN—Program Chair
Clinical Practice Nurse
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California
Charise Gleason, MSN, NP-C, AOCNP
Chief Advanced Practice Provider
Department of Hematology and Medical Oncology
Nell Hodgson Woodruff School of Nursing at Emory University
Amy Pierre, RN, MSN, ANP-BC
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey
This activity has been designed to meet the educational needs of oncology nurses, advanced oncology certified nurse practitioners, and other health care professionals involved in the care of patients with MM.
- Distinguish between the indicated uses, mechanisms of action, and safety of current and emerging agents for patients with relapsed/refractory MM
- Describe the toxicity profile for agents commonly used for the treatment of patients with relapsed/refractory MM
- Create patient-centered management plans with patients and other members of the care team to minimize the impact of treatment-related side effects
- Demonstrate how incorporating patient education and communication strategies can improve early detection of treatment-related adverse events
Oncology nurses will use the new knowledge to anticipate side effects associated with MM treatment and alleviate their impact on patients.
University of Texas Health Science Center at San Antonio is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Requirements for Successful Completion
To receive contact hours for this continuing education activity, the participant must:
- Complete 100% of the activity.
- Complete the posttest (achieving a passing grade of 80% or greater) and activity evaluation
A Certificate of Successful Completion will be awarded for 0.75 contact hours
- The certificate will be available for printing upon completion of the activity
For questions regarding CE credit, contact University of Texas Health Science Center at San Antonio at email@example.com.
Conflicts of Interest
A conflict of interest occurs when an individual has an opportunity to affect or impact educational content with which he or she may have a commercial interest or a potentially biasing relationship of a financial nature. All planners and presenters/authors/content reviewers must disclose the presence or absence of a conflict of interest relative to this activity. All potential conflicts are resolved prior to the planning, implementation, or evaluation of the continuing nursing education activity. All activity planning committee members and presenters/authors/content reviewers have submitted Conflict of Interest Disclosure forms. The planning committee members and presenters/authors of this CNE activity have disclosed the following relevant financial relationships related to the planning or implementation of this CNE activity:
Page Bertolotti, RN, BSN, OCN, has disclosed the following financial relationships:
- Speakers bureau: Celgene Corporation, Takeda Pharmaceuticals
Amy Pierre, RN, MSN, ANP-BC, has disclosed the following financial relationships:
- Speakers bureau: Amgen/Onyx
Reporting of Perceived Bias
Bias is defined by the ANCC COA as preferential influence that causes a distortion of opinion or of facts. Commercial bias may occur when a CNE activity promotes one or more product(s) (drugs, devices, services, software, hardware, etc.). This definition is not all-inclusive and participants may use their own interpretation in deciding if a presentation is biased. The ANCC COA is interested in the opinions and perceptions of participants at approved CNE activities, especially in the presence of actual or perceived bias in continuing education. Therefore, the ANCC invites participants to access their ANCC Accreditation Feedback Line to report any noted bias or conflict of interest in the education activity. The toll-free number is 1 (866)262-9730.
The opinions expressed in this educational activity are those of the presenters/authors and do not necessarily represent the views of University of Texas Health Science Center at San Antonio, the Multiple Myeloma Research Foundation, RedMedEd, Amgen, Bristol-Myers Squibb, or Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. University of Texas Health Science Center at San Antonio, the Multiple Myeloma Research Foundation, RedMedEd, Amgen, Bristol-Myers Squibb, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, do not recommend the use of any agent outside the labeled indications.
- Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
- A computer with an Internet connection
- Internet browser (PC): Google Chrome, Internet Explorer 9 or higher, or Firefox 26 or higher
- Internet browser (Mac): Google Chrome, Firefox 26 or higher, or Safari 5 or higher
- Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required
For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or firstname.lastname@example.org.
Copyright © 2016 University of Texas Health Science Center at San Antonio, the Multiple Myeloma Research Foundation, and RedMedEd. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.